PE20170328A1 - Compuestos de azetidiniloxifenilpirrolidina - Google Patents
Compuestos de azetidiniloxifenilpirrolidinaInfo
- Publication number
- PE20170328A1 PE20170328A1 PE2017000243A PE2017000243A PE20170328A1 PE 20170328 A1 PE20170328 A1 PE 20170328A1 PE 2017000243 A PE2017000243 A PE 2017000243A PE 2017000243 A PE2017000243 A PE 2017000243A PE 20170328 A1 PE20170328 A1 PE 20170328A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- azetidinyloxphenylpyrrolidine
- azetidinyloxyphenylpyrrolidine
- oxopropane
- methylpyrrolidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- WVEMMKKRMPLVQC-UHFFFAOYSA-N 2-(azetidin-1-yloxy)-1-phenylpyrrolidine Chemical class C1CCN1OC1N(C=2C=CC=CC=2)CCC1 WVEMMKKRMPLVQC-UHFFFAOYSA-N 0.000 abstract 1
- JIEGENLGWZJCAL-XHGXUTKZSA-N COC1=C(OC2CN(C2)C2=NC=C(Cl)C=C2)C=C(C=C1)[C@@H]1CN(C[C@@]1(C)[C@@H](C)O)C(=O)[C@@H](O)CO Chemical compound COC1=C(OC2CN(C2)C2=NC=C(Cl)C=C2)C=C(C=C1)[C@@H]1CN(C[C@@]1(C)[C@@H](C)O)C(=O)[C@@H](O)CO JIEGENLGWZJCAL-XHGXUTKZSA-N 0.000 abstract 1
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Se refiere a derivados de azetidiniloxifenilpirrolidina de la formula general, en donde: R1 es CH3, CD3, CN, Cl, CF3; y R es una de las formulas detalladas a continuacion. Estos compuestos son inhibidores de la PDE4 y se emplean en el tratamiento de la vejiga hiperactiva, incluso para aliviar sintomas asociados tales como la frecuencia y la urgencia, y otros trastornos. Entre los compuestos preferidos tenemos al siguiente: (2S)-3-[(3S,4S)-3-[(1R)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-cloropiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049485P | 2014-09-12 | 2014-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20170328A1 true PE20170328A1 (es) | 2017-04-19 |
Family
ID=54140711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017000243A PE20170328A1 (es) | 2014-09-12 | 2015-09-03 | Compuestos de azetidiniloxifenilpirrolidina |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10781202B2 (es) |
| EP (1) | EP3191466B1 (es) |
| JP (1) | JP6285610B2 (es) |
| KR (1) | KR101857931B1 (es) |
| CN (1) | CN106795137B (es) |
| AP (1) | AP2017009778A0 (es) |
| AR (1) | AR101696A1 (es) |
| AU (1) | AU2015315533B2 (es) |
| BR (1) | BR112017002852A2 (es) |
| CA (1) | CA2955634A1 (es) |
| CL (1) | CL2017000484A1 (es) |
| CO (1) | CO2017001389A2 (es) |
| CR (1) | CR20170050A (es) |
| DK (1) | DK3191466T3 (es) |
| EA (1) | EA030034B1 (es) |
| EC (1) | ECSP17014972A (es) |
| ES (1) | ES2770047T3 (es) |
| HR (1) | HRP20200119T1 (es) |
| HU (1) | HUE047551T2 (es) |
| IL (1) | IL250378A0 (es) |
| LT (1) | LT3191466T (es) |
| MX (1) | MX2017003138A (es) |
| NZ (1) | NZ729087A (es) |
| PE (1) | PE20170328A1 (es) |
| PH (1) | PH12017500459A1 (es) |
| PL (1) | PL3191466T3 (es) |
| PT (1) | PT3191466T (es) |
| RS (1) | RS59845B1 (es) |
| SG (1) | SG11201701225YA (es) |
| SI (1) | SI3191466T1 (es) |
| TN (1) | TN2017000047A1 (es) |
| TW (1) | TW201625591A (es) |
| WO (1) | WO2016040083A1 (es) |
| ZA (1) | ZA201700555B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105026395B (zh) | 2013-03-14 | 2018-07-20 | 勃林格殷格翰国际有限公司 | 取代的氮杂双环酰胺类组织蛋白酶c抑制剂及其药物组合物和制药用途 |
| NZ728684A (en) | 2014-09-12 | 2022-09-30 | Boehringer Ingelheim Int | Spirocyclic inhibitors of cathepsin c |
| CN111333625B (zh) * | 2018-12-18 | 2022-10-18 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物及其用途 |
| CN111333637B (zh) * | 2018-12-18 | 2022-07-29 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类衍生物及其制备方法 |
| JP7227380B2 (ja) * | 2018-12-18 | 2023-02-21 | 武漢人福創新薬物研発中心有限公司 | フェニルピロリジン化合物及びその用途 |
| CN112409333B (zh) * | 2019-08-23 | 2024-06-14 | 武汉人福创新药物研发中心有限公司 | 苯基吡咯烷类化合物 |
| TW202302587A (zh) | 2021-04-29 | 2023-01-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 異喹啉酮類化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6258833B1 (en) * | 1999-12-23 | 2001-07-10 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| OA12542A (en) * | 2001-01-31 | 2006-06-05 | Pfizer Prod Inc | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes. |
| SG166106A1 (en) | 2005-09-29 | 2010-11-29 | Bayer Schering Pharma Ag | Pde inhibitors and combinations thereof for the treatment of urological disorders |
| TW201206440A (en) | 2010-04-28 | 2012-02-16 | Astellas Pharma Inc | Prophylactic or therapeutic agent for diseases associated with pains in urinary organs |
| TWI617553B (zh) * | 2013-03-13 | 2018-03-11 | 美國禮來大藥廠 | 吖丁啶基氧苯基吡咯啶化合物 |
| WO2016033776A1 (en) * | 2014-09-04 | 2016-03-10 | Eli Lilly And Company | Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol |
-
2015
- 2015-08-26 TW TW104127990A patent/TW201625591A/zh unknown
- 2015-08-26 AR ARP150102734A patent/AR101696A1/es unknown
- 2015-09-03 AP AP2017009778A patent/AP2017009778A0/en unknown
- 2015-09-03 WO PCT/US2015/048267 patent/WO2016040083A1/en not_active Ceased
- 2015-09-03 TN TN2017000047A patent/TN2017000047A1/en unknown
- 2015-09-03 PE PE2017000243A patent/PE20170328A1/es unknown
- 2015-09-03 US US15/506,017 patent/US10781202B2/en active Active
- 2015-09-03 CR CR20170050A patent/CR20170050A/es unknown
- 2015-09-03 AU AU2015315533A patent/AU2015315533B2/en not_active Ceased
- 2015-09-03 PT PT157637638T patent/PT3191466T/pt unknown
- 2015-09-03 DK DK15763763.8T patent/DK3191466T3/da active
- 2015-09-03 BR BR112017002852A patent/BR112017002852A2/pt not_active Application Discontinuation
- 2015-09-03 KR KR1020177006717A patent/KR101857931B1/ko not_active Expired - Fee Related
- 2015-09-03 HR HRP20200119TT patent/HRP20200119T1/hr unknown
- 2015-09-03 MX MX2017003138A patent/MX2017003138A/es unknown
- 2015-09-03 SG SG11201701225YA patent/SG11201701225YA/en unknown
- 2015-09-03 PL PL15763763T patent/PL3191466T3/pl unknown
- 2015-09-03 HU HUE15763763A patent/HUE047551T2/hu unknown
- 2015-09-03 EA EA201790156A patent/EA030034B1/ru not_active IP Right Cessation
- 2015-09-03 LT LTEP15763763.8T patent/LT3191466T/lt unknown
- 2015-09-03 EP EP15763763.8A patent/EP3191466B1/en active Active
- 2015-09-03 SI SI201531038T patent/SI3191466T1/sl unknown
- 2015-09-03 JP JP2017513639A patent/JP6285610B2/ja active Active
- 2015-09-03 CN CN201580046264.3A patent/CN106795137B/zh active Active
- 2015-09-03 RS RS20200096A patent/RS59845B1/sr unknown
- 2015-09-03 CA CA2955634A patent/CA2955634A1/en not_active Abandoned
- 2015-09-03 NZ NZ729087A patent/NZ729087A/en not_active IP Right Cessation
- 2015-09-03 ES ES15763763T patent/ES2770047T3/es active Active
-
2017
- 2017-01-24 ZA ZA2017/00555A patent/ZA201700555B/en unknown
- 2017-01-31 IL IL250378A patent/IL250378A0/en unknown
- 2017-02-13 CO CONC2017/0001389A patent/CO2017001389A2/es unknown
- 2017-03-01 CL CL2017000484A patent/CL2017000484A1/es unknown
- 2017-03-10 PH PH12017500459A patent/PH12017500459A1/en unknown
- 2017-03-14 EC ECIEPI201714972A patent/ECSP17014972A/es unknown
-
2019
- 2019-09-13 US US16/570,422 patent/US20200002318A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170328A1 (es) | Compuestos de azetidiniloxifenilpirrolidina | |
| CY1123661T1 (el) | Κρυσταλλικη μορφη ενος αναστολεα της mdm2 | |
| GT201800020A (es) | Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) | |
| MX2017002670A (es) | Inhibidores de glucosidasa. | |
| EA201500652A1 (ru) | Дифторметилникотиновые инданилкарбоксамиды | |
| EA201592126A1 (ru) | 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| CO6771439A2 (es) | Inhibidores de benzodioxano de la producción de leucotrieno | |
| EA201490287A1 (ru) | Новые замещенные производные индола в качестве модуляторов гамма-секретазы | |
| EA201491623A1 (ru) | Замещенные пирролидин-2-карбоксамиды | |
| MX372962B (es) | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). | |
| EA201490357A1 (ru) | Индазолы | |
| EA201790384A1 (ru) | Полиморфы селинексора | |
| PE20151748A1 (es) | Inhibidores de bace1 | |
| EA201490272A1 (ru) | Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы | |
| PE20151025A1 (es) | Nuevos derivados de piridina | |
| PE20180233A1 (es) | Nuevos compuestos biciclicos como inhibidores duales de atx / ca | |
| UY36651A (es) | Compuestos antiestrogénicos | |
| EA201600121A1 (ru) | Новые индольные и пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| AR092555A1 (es) | 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc | |
| EA201690561A1 (ru) | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i | |
| EA201591498A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| AR099300A1 (es) | Hexahidrofuropirroles como inhibidores de pde1 | |
| ECSP17013015A (es) | (2S)-3-[(3S,4S)-3-[(1R)-1-hidroxietil]-4-(4-metoxi-3-{[1-(5-metilpiridin-2-il)azetidin-3-il]oxi}fenil)-3-metilpirrolidin-1-il]-3-oxopropano-1,2-diol Cristalino | |
| EA201590014A1 (ru) | Азетидиновые и пиперидиновые соединения, подходящие для применения в качестве ингибиторов pde10 | |
| UY36023A (es) | “derivados cristalinos de (s)-1-((2r,3r,4s,5s)-5-alil-3-metoxi-4-(tosilmetil) tetrahidrofuran-2-il)-3-aminopropan-2-ol “. |